These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24641673)

  • 21. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
    Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria.
    Palliyil S; Broadbent ID
    Curr Opin Pharmacol; 2009 Oct; 9(5):566-70. PubMed ID: 19726227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type III secretion: the bacteria-eukaryotic cell express.
    Mota LJ; Sorg I; Cornelis GR
    FEMS Microbiol Lett; 2005 Nov; 252(1):1-10. PubMed ID: 16216444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
    Keyser P; Elofsson M; Rosell S; Wolf-Watz H
    J Intern Med; 2008 Jul; 264(1):17-29. PubMed ID: 18393958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fermentation preparation of recombinant Vibrio anguillarum vaccine with heterogeneous antigen display.
    Wang S; Liu Q; Cai M; Wang Q; Zhang Y
    Prep Biochem Biotechnol; 2013; 43(1):79-94. PubMed ID: 23215656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity.
    Schmidt A; Schaffelhofer S; Müller K; Röllinghoff M; Beuscher HU
    Microb Pathog; 1999 Apr; 26(4):221-33. PubMed ID: 10089162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacterial ghosts: non-living candidate vaccines.
    Szostak MP; Hensel A; Eko FO; Klein R; Auer T; Mader H; Haslberger A; Bunka S; Wanner G; Lubitz W
    J Biotechnol; 1996 Jan; 44(1-3):161-70. PubMed ID: 8717400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Polyvalent Vaccine Candidates From Extracellular Secretory Proteins in
    Peng YM; Tao JJ; Kuang SF; Jiang M; Peng XX; Li H
    Front Immunol; 2021; 12():736360. PubMed ID: 34671354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pseudomonas aeruginosa Type III Secretory Toxin ExoU and Its Predicted Homologs.
    Sawa T; Hamaoka S; Kinoshita M; Kainuma A; Naito Y; Akiyama K; Kato H
    Toxins (Basel); 2016 Oct; 8(11):. PubMed ID: 27792159
    [No Abstract]   [Full Text] [Related]  

  • 30. An Aeromonas salmonicida type IV pilin is required for virulence in rainbow trout Oncorhynchus mykiss.
    Masada CL; LaPatra SE; Morton AW; Strom MS
    Dis Aquat Organ; 2002 Aug; 51(1):13-25. PubMed ID: 12240967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diminished LcrV secretion attenuates Yersinia pseudotuberculosis virulence.
    Bröms JE; Francis MS; Forsberg A
    J Bacteriol; 2007 Dec; 189(23):8417-29. PubMed ID: 17873031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel in vivo inducible expression system in Edwardsiella tarda for potential application in bacterial polyvalence vaccine.
    Mu W; Guan L; Yan Y; Liu Q; Zhang Y
    Fish Shellfish Immunol; 2011 Dec; 31(6):1097-105. PubMed ID: 21964456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of structural variations of polysaccharide antigens in the pathogenicity of Gram-negative bacteria.
    Lukácová M; Barák I; Kazár J
    Clin Microbiol Infect; 2008 Mar; 14(3):200-6. PubMed ID: 17986210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
    Neely AN; Holder IA; Wiener-Kronish JP; Sawa T
    Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates.
    Sizemore DR; Warner EA; Lawrence JA; Thomas LJ; Roland KL; Killeen KP
    Hum Vaccin Immunother; 2012 Mar; 8(3):371-83. PubMed ID: 22327496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The type III secretion system tip complex and translocon.
    Mueller CA; Broz P; Cornelis GR
    Mol Microbiol; 2008 Jun; 68(5):1085-95. PubMed ID: 18430138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the vaccine potential of a cytotoxic protease and a protective immunogen from a pathogenic Vibrio harveyi strain.
    Cheng S; Zhang WW; Zhang M; Sun L
    Vaccine; 2010 Jan; 28(4):1041-7. PubMed ID: 19897068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RTX toxins in Pasteurellaceae.
    Frey J; Kuhnert P
    Int J Med Microbiol; 2002 Sep; 292(3-4):149-58. PubMed ID: 12398206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle.
    Nougayrède JP; Taieb F; De Rycke J; Oswald E
    Trends Microbiol; 2005 Mar; 13(3):103-10. PubMed ID: 15737728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis.
    Aanæs K
    J Cyst Fibros; 2013 Sep; 12 Suppl 2():S1-20. PubMed ID: 24064077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.